JJDC Newsroom

Clicking on any of the links below will take you to a Web site to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every Web site you visit.

J&J News

Click here to access the latest news from our parent company, Johnson & Johnson.

Portfolio Company News

Find the latest investment news from our portfolio companies.

October 9, 2014
Bavarian Nordic A/S: Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson

June 9, 2014
CVRx® Achieves Two Significant Milestones for its Heart Failure and Hypertension Businesses

January 29, 2014
Celladon Announces Pricing of Initial Public Offering

January 7, 2014
Barostim Therapy™ Projected to be Cost-Effective in Treating Resistant Hypertension

December 17, 2013
Aquinox Pharmaceuticals commences Phase 2 clinical trial of AQX-1125 in Chronic Obstructive Pulmonary Disease

December 11, 2013
Celladon Corporation Announces Receipt of EMA Scientific Advice for MYDICAR® and Initiation of AGENT-HF Trial

December 5, 2013
Genocea Biosciences Initiates Phase 1 Study of Vaccine Candidate GEN-004 to Prevent Infections Caused By Pneumococcus

November 5, 2013
CVRx® & DaVita Announce Strategic Partnership

October 30, 2013
CVRx® Closes $12 Million Additional Financing

October 29, 2013
ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine

October 9, 2013
Catalyst Biosciences and ISU Abxis Announce Collaboration to Develop Next-Generation Best-In-Class Factor IX Therapeutics

October 9, 2013
USGI Medica Receives FDA Approval to Launch Head-to-Head Pivotal Study to Determine Safety, Effectiveness of Incisionless, Endoscopic Weight Loss Procedure

October 3, 2013
Merus Secures €31 Million in Series B Round Extension

September 26, 2013
Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure

September 19, 2013
Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard

September 17, 2013
Five Prime Therapeutics Announces Pricing of Initial Public Offering

September 12, 2013
Genocea Reports Positive Initial Phase 1/2a Results for Gen-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (Hsv-2), at ICAAC 2013

September 10, 2013
First Patient Enrolls in U.S. Salus Trial Evaluating Direct Flow Medical® Transcatheter Aortic Heart Valve System

September 4, 2013
Results of First Multi-Center Trial of NovoTTF? Therapy in Combination with Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) Published in Lung Cancer

September 3, 2013
Galien Foundation Selects NovoTTF™ Therapy as a Finalist for the 2013 Prix Galien USA Award

September 3, 2013
Coherex Medical Announces CE Mark for the WaveCrest LAA Occlusion System

July 29, 2013
ReVision Optics Closes $55 Million Financing

July 23, 2013
Aquinox Pharmaceuticals commences Phase II clinical trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis

July 10, 2013
ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes

June 27, 2013
Rodin Therapeutics Applies Insights of Epigenetics to Neurological Disorders

June 27, 2013
Vedanta Enters Collaboration with Johnson & Johnson Innovation Center in Boston

June 18, 2013
PhaseBio Expands Clinical Development of Vasomera, an Investigational Treatment for Cardiopulmonary Diseases

June 4, 2013
Protagonist Therapeutics Raises $14 Million in Series B Venture Financing

June 4, 2013
PhaseBio Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes

April 22, 2013
Canadian Biotech Industry Recognizes Top Performers

April 3, 2013
Aquinox Pharmaceuticals Completes US $18 Million Series C Financing

March 19, 2013
UCB AND Five Prime Therapeutics Announce Strategic Discovery Collaboration

March 7, 2013
Nevro Corp. Closes $48 Million in New Financing

January 3, 2013
Welsh, Carson, Anderson & Stowe Completes Acquisition Of GetWellNetwork

December 12, 2012
Biocartis Completes €34,5 Million ($44,5 Million) Series D Fund Raising

December 11, 2012
23andMe Raises More Than $50 Million in New Financing

December 4, 2012
PhaseBio Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as Chief Business Officer

October 10, 2012
Genocea Closes $30 Million in Series C Financing

October 2, 2012
Lonza and Celladon Announce Manufacturing Agreement for MYDICAR®

August 29, 2012
Celladon Corporation Announces First Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure

August 21, 2012
Allergan and Molecular Partners Enter into Exclusive Alliance

August 21, 2012
PhaseBio Pharmaceuticals Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes

August 15, 2012
Genocea Initiates a Phase 1/2a Study with Its Therapeutic Vaccine Candidate for Herpes Simplex Virus-2 (HSV-2)

August 8, 2012
Publication Of Clinical Trial Data For New Snoring Therapy

July 19, 2012
Celladon Corporation Receives Patent from United States Patent and Trademark Office

June 13, 2012
Lonza and BioWa Sign License Agreements with FivePrime Therapeutics for Use of Their POTELLIGENT® CHOK1SV Cell Line for Therapeutic Antibody Development

June 7, 2012
Astute Medical Completes $40.4 Million Series C Financing

June 5, 2012
PhaseBio Pharmaceuticals Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing For Advancement of Metabolic and Cardiovascular Product Portfolio

June 4, 2012
Five Prime Therapeutics Announces That Human Genome Sciences Files U.S. IND for HGS1036/FP-1039 FGF Ligand Trap

May 23, 2012
Nevro Receives FDA Approval to Initiate Landmark U.S. Randomized Pivotal Trial of Innovative Chronic Pain Treatment

May 21, 2012
Study Results of Novocure's NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer

May 16, 2012
Mitralign Raises $35 Million Series D Financing

May 14, 2012
Novocure Announces Launch of Recurrent Glioblastoma Product Website

May 7, 2012
Celladon Corporation Completes Second Close of Recent Venture Financing

May 4, 2012
Genocea Highlights Key Progress in the Development of its First Vaccine Candidate, Targeting HSV-2

April 20, 2012
Synthon acquires LEX Systemâ„  from Biolex Therapeutics

April 17, 2012
Five Prime Therapeutics Announces Second Strategic Alliance With GlaxoSmithKline

March 13, 2012
pSivida Announces Second Tech Evaluation Agreement with its BioErodible Durasert Technology Agreement with Neuron Systems Focuses on Dry AMD

February 22, 2012
PhaseBio Launches Clinical Program to Evaluate Novel VPAC2 Agonist for Cardiovascular Disease

February 15, 2012
Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure

February 6, 2012
Five Prime Therapeutics Confirms Appointment of Lewis T. "Rusty" Williams as CEO and Announces the Appointment of Brian Atwood as Chairman of the Board

January 23, 2012
PowerVision Closes Additional $12.5MM Financing

January 5, 2012
Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences

December 8, 2011
Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat

November 29, 2011
Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch

October 20, 2011
Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer

October 20, 2011
Syntaxin and Ipsen Enter into a Strategic Agreement to Develop Novel Botulinum-toxin Therapeutics

October 18, 2011
iScience Interventional Announces Clinical and Commercial Supply Agreement

August 30, 2011
GI's successful raising lifts IPO market dynamics

August 22, 2011
Isconova and Genocea expand collaboration

August 8, 2011
Johnson & Johnson invests in Israel's LifeBond

July 20, 2011
SuperGen Completes Acquisition of Astex Therapeutics

July 19, 2011
Nevro Corp Closes $58 Million in New Financing

July 18, 2011
Atlas Genetics Ltd Completes £16.9 million Series B Financing led by Novartis Venture Funds

June 27, 2011
Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation

June 16, 2011
Five Prime Therapeutics Provides an Update on its Strategic Discovery Collaborations with Pfizer and GlaxoSmithKline

June 15, 2011
Spinal Modulation Secures $30 Million Series D Financing

May 23, 2011
Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo

May 19, 2011
Metabolex Initiates Phase 2 Trial Of Arhalofenate

May 11, 2011
Light Sciences Oncology Elects Dennis Langer, M.D., J.D. to Its Board of Directors

May 4, 2011
Allergan and Molecular Partners Enter into an Exclusive License Agreement For MP0112 For the Treatment of Retinal Diseases

March 8, 2011
Astute Medical Completes $13 Million Financing with Existing Stockholders

February 16, 2011
New pneumococcal vaccine approach successful in early tests

January 6, 2011
Zeo, Inc. Announces $12.3 Million Venture Financing

January 3, 2011
Genocea Biosciences Closes $35 Million Series B Financing

November 30, 2010
PhaseBio Launches Clinical Program to Test Lead Product for Sustained 24/7 Glycemic Control in Type 2 Diabetics

November 11, 2010
Syntaxin raises £18 million in new financing

November 9, 2010
23andMe Raises More Than $22 million in Series C Financing

July 15, 2010
Biolex and Merial Broaden Collaboration

July 8, 2010
NeuroPace Submits PMA Application for FDA Approval of Novel Investigational Device for Epilepsy

June 22, 2010
Metabolex Enters Into Type 2 Diabetes Development and License Agreement

June 17, 2010
Aquinox Pharmaceuticals completes US $25 million Series B financing

May 18, 2010
Breathe Technologies Secures $23 Million in Series C Financing

May 10, 2010
Astute Medical Announces $26.5 Million Series B Financing

April 30, 2010
Molecular Partners progresses DARPin into first-in-humans clinical studies

April 28, 2010
Celladon Corp. Announces that MYDICAR® Meets Primary Endpoint in Phase 2 Trial for Treatment of Advanced Heart Failure

April 15, 2010
Biolex Announces Presentation at EASL OF Interim Results From Select-2 Phase2b Trial of Locteron® in Chronic Hepatitis C

April 13, 2010
Encouraging data from three Astex collaborative programmes to be presented at the 101st American Association for Cancer Research (AACR) Annual Meeting 2010

April 7, 2010
iScience Interventional, Inc Enters into a Collaborative Supply Agreement with Centocor Research and Development, Inc on a Minimally-Invasive Approach to Deliver Cell Therapies

March 3, 2010
Study Demonstrates People Living with Type 2 Diabetes and Obesity Can Be Successfully Treated with GI Dynamics' EndoBarrier™ Gastrointestinal Liner for 12 Months

February 25, 2010
Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase 3 MCRC Trial

February 24, 2010
Five Prime Therapeutics, Inc. Announces Milestone for Therapeutic Program

February 12, 2010
CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial

January 20, 2010
Ethicon Completes Acquisition of Acclarent

January 7, 2010
GI Dynamics Receives Strategic Investment from Medtronic, Inc.

January 7, 2010
PhaseBio Pharmaceuticals, Inc. Raises $25 Million in Series B Funding, Initiates Collaboration with OSI Pharmaceuticals

January 6, 2010
Insound® Medical Acquired by Sonova

December 15, 2009
Molecular Partners Secures CHF 46 million in Series B Financing Led by Essex Woodlands Health Ventures

November 4, 2009
Spinal Modulation Completes $27.4 Million Financing

August 17, 2009
NeuroSearch announces drug discovery and drug development alliance with Janssen Pharmaceutica NV

June 22, 2009
CoAxia, Inc. Announces $21.5M Series D Financing

April 23, 2009
iScience Interventional receives $20.5 million in Series F funding

February 19, 2009
GI Dynamics Closes an Additional $15 Million in Series C Financing

January 7, 2009
GI Dynamics Receives ISO Certification and European CE Mark Approval for the EndoBarrier™ Gastrointestinal Liner System

December 3, 2008
Catalyst Biosciences Raises $40 Million in Series C Financing

November 19, 2008
Tengion Announces Second Closing of Series C Financing

October 6, 2008
Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron® in Hepatitis C